Asset profile

Ribociclib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(42 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (4)

September 2026 (1)

Phase 1/2KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer …Active not recruiting

Est. primary completion 2026-09-30 · NCT05358249 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 1/2Triple Negative Breast CancerActive not recruiting

Est. primary completion 2026-10 · NCT03090165 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-30 · NCT05573555 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (10)

January 2027 (1)

Phase 2HER2-positive Advanced Breast CancerEnrolling by invitation

Est. primary completion 2027-01-10 · NCT06481956 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (2)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-02-19 · NCT06065748 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (3)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8 …Active not recruiting

Est. primary completion 2027-04-01 · NCT05319873 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07-31 · NCT07054190 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-07-31 · NCT04055493 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-08-04 · NCT06188520 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (12)

January 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-02 · NCT07195227 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-07-01 · NCT06062498 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08-31 · NCT06377852 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-09-25 · NCT06726148 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)

Phase 1/2Advanced Solid TumorsNot yet recruiting

Est. primary completion 2028-10-28 · NCT07767474 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (4)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-12 · NCT07618390 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12 · NCT07085767 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-19 · NCT07405801 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT05816655 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (8)

February 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-02-28 · NCT07647328 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (2)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-09-01 · NCT07164976 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2029-10-01 · NCT05296746 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (6)

February 2030 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-02-10 · NCT07400523 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2030 (1)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2030-05-29 · NCT03701334 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2030-10-01 · NCT07423611 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)

June 2031 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2031-06-30 · NCT06849947 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)

November 2033 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2033-11-30 · NCT07237256 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.